Lansik’s AI-Based Blood Sugar Solution Glucofit Secures KRW 1.2 Billion in Pre-Series A Funding
Lansik, the operator of South Korea’s AI blood sugar management solution ‘Glucofit,’ has raised KRW 1.2 billion in pre-Series A funding. This investment round was led by BonAngels Venture Partners, with participation from Capstone Partners, InfoBank, and dcamp.
Launched in November 2022, Glucofit is Korea’s first blood sugar management solution, based on medical evidence that individuals have different blood sugar responses to the same food. It uses a Continuous Glucose Monitoring (CGM) sensor attached to the arm and linked to the Glucofit app, allowing users to measure their blood sugar data in real-time without needing to draw blood. Currently, the app integrates with Abbott’s ‘FreeStyle Libre’ CGM, and plans are in place to include Dexcom‘s ‘Dexcom G7’ within the first half of this year.
Through the Glucofit app, users can access real-time blood sugar measurements and analysis, understanding how their food intake and lifestyle habits impact their blood sugar levels. Additionally, by logging food intake, the AI identifies the type of food, the increase in blood sugar, and nutritional components, offering a diet plan for managing blood sugar and providing personalized feedback in real-time. This aids not only in managing blood sugar but also in supporting weight loss, with the app offering professional consultations with practicing doctors on a one-on-one basis.
Glucofit primarily targets the 15 million prediabetic patients and those interested in healthy weight management. The strategy for this year includes expanding into a B2B business model through collaborations with employee health management programs, health centers such as gyms, and medical clinics and hospitals.
With this latest round of funding, Lansik plans to focus on service enhancement to attract new customers and improve customer satisfaction. Efforts will include refining its AI blood sugar prediction algorithm, which predicts blood sugar levels without a CGM, and providing extensive feedback through AI doctors using large language models, establishing a competitive edge.
BonAngels partner Yoon Jong-il, who led the investment, stated, “Despite the significant time since the commercialization of continuous glucose monitors, there has been a lack of accessible services. Considering the profound impact of blood sugar management on health, we highly value Glucofit’s potential to make monitoring and managing blood sugar levels easy for the general public.”
Yang Hyuk-yong, CEO of Lansik, expressed his ambitions, saying, “Obesity and metabolic diseases are a global problem, with the CGM market growing at an annual rate of 12% worldwide. Through our AI blood sugar management solution, Glucofit, we aim to not only address the domestic market but also prevent diseases in 1 billion people globally, becoming a global blood sugar management solution.”
[Korean bioHealth Startups News]
- Rexpharm Forms MOU with Timely Basket to Develop and Distribute Health Foods in U.S.
- SEOUL BIOHUB Global Center Opens, Aiming to Boost Global BioTech Competitiveness
- Delight Room Invests in Soundable Health for Advanced Sound Analysis in Healthcare
- Apollon Secures 2.3 Billion KRW in Funding for Innovative Needle-Free CGM Technology
- Korean Space Medicine Startup SpaceLiintech Lands 4 Billion KRW Series A Funding
- ArtBlood Secures KRW 6.5 Billion in Series A for Synthetic Blood Production
- GLOUD Raises 3B KRW in Pre-Series A for Global Dental Digital Transformation Expansion
- Protium Science and HK innoN Forge Strategic Investment & Partnership
- LabInCube Raises KRW 5.1B in Series A for MOF Material Development
- Prevenotics Secures Investment for AI-Based Cancer Prevention from 500 Global
